uniQure (QURE) AI Stock Analysis

• Market Cap: $895.98M
• Dividend Yield: N/A
• Average Volume (3M): 1.07M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.65
• Revenue Growth: -48.25%
• EPS Growth: 33.77%
• Country: US
• Employees: 209
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.69
• Shares Outstanding: 54,866,930
• 10 Day Avg. Volume: 713,785
• 30 Day Avg. Volume: 1,069,845
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 63.40
• Enterprise Value/Gross Profit: 76.75
• Enterprise Value/Ebitda: -6.25
• 1Y Price Target: $39.25
• Price Target Upside: 140.36% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

• Rating: 54 Neutral
• Price Target: $16.00 ▼(-2.02% Downside)

uniQure's overall stock score reflects significant financial challenges, including declining revenues and a weak balance sheet, which are the most impactful factors. While technical analysis shows positive momentum and recent corporate events provide strategic opportunities, the negative valuation metrics and mixed earnings call sentiment temper the overall outlook.

Positive Factors

Clinical Advancements

UniQure delivered a clean and focused update, with regulatory, manufacturing, and clinical progress keeping AMT-130 on track for a Biologics License Application filing and potential approval.

Regulatory Progress

FDA alignment and CMC progress keep AMT-130 on track for accelerated approval.

Therapy Development

AMT-130 is well-positioned as the first potential disease-modifying treatment for Huntington's disease.

Negative Factors

Leadership Changes

The announcement of Dr. Prasad as the head of CBER put pressure on the stock due to his outspoken views on accelerated approval and gene therapy.

Market Pressure

Several gene therapy programs have recently received clinical holds or complete response letters, which has placed some pressure on QURE shares.

Regulatory Uncertainty

The stock has been volatile due to regulatory uncertainty and has remained range-bound.

uniQure Business Overview & Revenue Model

Company Description

uniQure N.V. is a leading gene therapy company focused on delivering transformative therapies for patients with severe diseases. The company specializes in developing innovative gene therapies for genetic disorders, particularly in the areas of hemophilia, Huntington's disease, and other neurodegenerative diseases. uniQure's proprietary AAV (adeno-associated virus) technology platform enables the development of durable gene therapies that aim to provide long-lasting treatment solutions.

How the Company Makes Money

uniQure generates revenue primarily through the commercialization of its gene therapy products, which include marketed products like Zynteglo for beta-thalassemia and other pipeline therapies in late-stage clinical development. The company also earns revenue from research collaborations and licensing agreements with pharmaceutical and biotechnology companies. These partnerships may include upfront payments, milestone payments based on the achievement of specific developmental or regulatory goals, and royalties on future sales of licensed products. Additionally, uniQure may benefit financially from government grants and funding aimed at supporting innovative research in gene therapy.

uniQure Financial Statement Overview

Summary

uniQure is facing significant financial challenges with declining revenues, negative profit margins, and a weak balance sheet. The company's high debt levels and negative equity position raise concerns about its financial stability. While there is a slight improvement in free cash flow, the overall financial health of the company is precarious, requiring strategic interventions to improve profitability and strengthen the balance sheet.

Income Statement

uniQure's income statement reflects significant challenges with declining revenues and negative profit margins. The TTM data shows a sharp revenue decline of 29% and a net profit margin of -13.88%, indicating substantial losses. Despite a high gross profit margin of 82.61% in the TTM, the company struggles with negative EBIT and EBITDA margins, highlighting operational inefficiencies.

Balance Sheet

The balance sheet reveals a concerning financial position with negative stockholders' equity and a high debt-to-equity ratio of -16.66 in the TTM. This indicates financial instability and potential solvency issues. The return on equity is also negative, reflecting ongoing losses and poor returns for shareholders.

Cash Flow

uniQure's cash flow statement shows a slight improvement in free cash flow growth at 4.33% in the TTM, but the operating cash flow remains negative, indicating cash burn. The free cash flow to net income ratio is slightly above 1, suggesting that the company is generating enough cash to cover its net losses, but the overall cash flow situation remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.34M	27.12M	15.84M	106.48M	524.00M	37.51M
Gross Profit	11.84M	8.79M	2.21M	103.14M	499.03M	-84.89M
EBITDA	-145.35M	-160.75M	-253.10M	-108.02M	319.00M	-126.97M
Net Income	-199.00M	-239.56M	-308.48M	-126.79M	329.59M	-125.02M
Balance Sheet
Total Assets	584.89M	556.54M	831.69M	704.96M	809.18M	340.39M
Cash, Cash Equivalents and Short-Term Investments	376.97M	367.52M	617.89M	352.84M	556.26M	244.93M
Total Debt	66.70M	66.06M	138.41M	142.89M	135.72M	71.54M
Total Liabilities	588.89M	563.29M	624.02M	228.96M	213.40M	96.49M
Stockholders Equity	-4.00M	-6.75M	207.67M	476.01M	595.78M	243.91M
Cash Flow
Free Cash Flow	-174.26M	-186.10M	-153.08M	-162.75M	270.52M	-144.31M
Operating Cash Flow	-173.44M	-182.73M	-145.93M	-145.06M	287.96M	-134.83M
Investing Cash Flow	114.22M	162.97M	-205.69M	-182.73M	-67.39M	-9.48M
Financing Cash Flow	21.18M	-59.49M	362.72M	1.45M	94.86M	7.44M

uniQure Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 16.33
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QURE, the sentiment is Positive. The current price of 16.33 is above the 20-day moving average (MA) of 15.02, above the 50-day MA of 14.66, and above the 200-day MA of 13.43, indicating a bullish trend. The MACD of 0.44 indicates Negative momentum. The RSI at 63.97 is Neutral, neither overbought nor oversold. The STOCH value of 71.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QURE.

uniQure Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CVAC	74 Outperform	$1.21B	5.91	34.46%	―	799.36%	―
NTLA	55 Neutral	$1.22B	―	-56.95%	―	14.99%	14.42%
QURE	54 Neutral	$895.98M	―	-427.47%	―	-48.25%	33.77%
Sector *	51 Neutral	$7.86B	-0.26	-41.41%	2.22%	22.87%	-2.01%
DAWN	50 Neutral	$769.26M	―	-24.75%	―	2190.50%	52.85%
SYRE	43 Neutral	$996.01M	2.31	-41.00%	―	―	-429.68%
RCKT	40 Underperform	$353.92M	―	-69.65%	―	―	10.36%

uniQure Corporate Events

uniQure Announces $200 Million Sales Agreement

On July 29, 2025, uniQure N.V. announced a sales agreement with Leerink Partners LLC for an at-the-market offering program, allowing the company to sell its ordinary shares worth up to $200 million. This strategic move provides uniQure with flexibility in raising capital, potentially enhancing its financial position and supporting its ongoing operations in the competitive gene therapy market.

uniQure Shareholders Approve Key Proposals at Annual Meeting

On June 11, 2025, uniQure held its Annual Meeting where shareholders voted on several key proposals. The meeting resulted in the re-election of Matthew Kapusta as executive director and Dr. Robert Gut and Dr. Jeremy Springhorn as non-executive directors, each to serve until the 2028 annual general meeting. Additionally, all other proposals, including the adoption of the 2024 Dutch statutory annual accounts, discharge of board members’ liabilities, and various authorizations related to shares and compensation, were approved.

uniQure Aligns with FDA for AMT-130 BLA Approval

On June 2, 2025, uniQure announced alignment with the FDA on key components necessary for a Biologics License Application (BLA) for AMT-130, a gene therapy for Huntington’s disease. This alignment supports an accelerated approval pathway, with a BLA submission planned for early 2026. The company is leveraging extensive clinical data and FDA guidance to pursue the first disease-modifying treatment for Huntington’s disease, reflecting a significant step forward in addressing this unmet medical need.